Comparison of lenvatinib plus pembrolizumab versus first-line systemic chemotherapy for advanced intrahepatic cholangiocarcinoma: a real-world retrospective study
This study demonstrated that Len-P is promising for the treatment of advanced ICC, with highly improved safety. It emerges as a viable treatment alternative for advanced iCCA. Inflammation-based scores show potential utility in identifying individuals likely to benefit from Len-P therapy.
Authors
- Dandan Hu (ORCID: https://orcid.org/0000-0001-7905-8536)
- Yangxun Pan (ORCID: https://orcid.org/0000-0002-3887-5852)
- Yizhen Fu (ORCID: https://orcid.org/0000-0003-1919-7176)
- Zhenyun Yang (ORCID: https://orcid.org/0000-0001-9526-7741)
- Zili Hu (ORCID: https://orcid.org/0000-0002-1987-730X)
- Minshan Chen (ORCID: https://orcid.org/0000-0002-6741-7498)
- Jinbin Chen (ORCID: https://orcid.org/0000-0002-6619-1247)
- Juncheng Wang (ORCID: https://orcid.org/0000-0003-0972-9511)
- Zhiwen Hu (ORCID: https://orcid.org/0000-0002-3472-6083)
- Zhongguo Zhou
- Yao‐Jun Zhang (ORCID: https://orcid.org/0000-0001-8357-5544)
- Weijie Wu
Institutions
- Sun Yat-sen University (CN)
- Sun Yat-sen University Cancer Center (CN)
Publication Details
- Journal
- Frontiers in Immunology
- Published
- 2024-11-29
- DOI
- https://doi.org/10.3389/fimmu.2024.1494520
- Citations
- 3
- Primary Topic
- Cholangiocarcinoma and Gallbladder Cancer Studies
- Type
- article
- Field-Weighted Citation Impact
- 1.72
Funders
- National Natural Science Foundation of China
- China Postdoctoral Science Foundation
- Guangzhou Municipal Science and Technology Project
- Basic and Applied Basic Research Foundation of Guangdong Province